VGXI Inc, a Texas-based contract developer and manufacturer (CDMO) specialising in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines and RNA medicines, announced on Wednesday the appointment of Stephanie Burke as chief accounting officer (CAO).
Burke has more than a decade of accounting and leadership expertise. She has served in leadership roles managing both the VGXI Accounting/Finance and Materials teams.
Previously, Burke was financial controller at Manuli RYCO / Fliuconnecto and general manager of International Expo Service.
VGXI's CEO, Young Park, said: "Stephanie has been an invaluable member of the VGXI team since 2015. Her exceptional financial acumen coupled with her leadership skills make her the ideal candidate for the chief accounting officer position.
"This well-deserved promotion recognises the significant contributions Stephanie has made to VGXI during her tenure and she will undoubtedly play a critical role in shaping our financial strategies as we enter our next phase."
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma